SCHEMBL7512341

SCHEMBL7512341

O=Cc1ccc(-c2nc3cc(Cl)c(Cl)cc3[nH]2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 3/20 0.63
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
CHEK2 O96017 3/20 0.48
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
KDM4E B2RXH2 2/20 0.46
TP53 P04637 2/20 0.46
HSD17B10 Q99714 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CCR2 P41597 1/20 0.46
APP P05067 1/20 0.46
GAA P10253 1/20 0.46
NFKB1 P19838 1/20 0.46
SNCA P37840 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7513796 0.82 HPSE (0.60) NPC1RAB9A
SCHEMBL20982796 0.81 MEN1 (0.57) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL7518468 0.80 RHEB (0.54) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL7514120 0.80 NPC1 (0.49) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL25206796 0.80 RHEB (0.69) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL10736415 0.80 RHEB (0.69) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL30943399 0.80 RHEB (0.69) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL6324494 0.80 RHEB (0.69) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL9000174 0.79 RHEB (0.73) RHEBMEN1KMT2ANPC1RAB9A
SCHEMBL30615082 0.79 RHEB (0.73) RHEBMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 RHEB 1710/4885MEN1 2033/4885KMT2A 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.